Skip to main content
. Author manuscript; available in PMC: 2015 Apr 27.
Published in final edited form as: J Nucl Med. 2014 Nov 5;55(12):2045–2049. doi: 10.2967/jnumed.114.145185

FIGURE 2.

FIGURE 2

Genetic or pharmacologic inhibition of AR suppresses STEAP1 expression in CWR22Pc. (A) Stable suppression of AR with shRNA results in suppression of STEAP1 protein. CWR22Pc cells were transduced with 1 of 5 pools of lentiviral particles harboring discrete hairpins to AR (shAR1–5) or nontargeting hairpin (shNT). Cell lysates were collected from stable lines after puromycin selection for immunoblotting. AR was potently downregulated with concomitant suppression of STEAP1 protein. Data are representative of 3 independent experiments. (B) Intact animals (n = 5/treatment arm) bearing CWR22Pc tumors were treated with vehicle (veh.), orchiectomy (orch.), or orchiectomy with subsequent daily oral gavage of enzalutamide (enz.) (30 mg/kg). Tumor volume measurements showed that orchiectomy reduced rate of tumor growth, compared with vehicle, and combination therapy resulted in tumor regression over 28 d. (C) Representative immunoblot from CWR22Pc xenografts treated for 7 d shows that orchiectomy alone or orchiectomy + enzalutamide results in dramatic reduction of STEAP1 expression.